Josep Serra

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With <i>HER2</i> Alterations: A Phase Ia Dose-Escalation Study

John V. Heymach, Frans L. Opdam, Minal Barve et al. · Journal of Clinical Oncology · 2025 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

Albert Font, Begoña Mellado, Miguel Ángel Climent et al. · British Journal of Cancer · 2023 · 11 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.

John V. Heymach, Frans L. Opdam, Minal Barve et al. · Journal of Clinical Oncology · 2023 · 10 citations

Medicine, Oncology, Pharmacotherapy +17